Last updated on November 2017

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies


Brief description of study

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies

Detailed Study Description

The purpose of this study is to see if GS-9073 can benefit people with CLL. This study will also investigate the safety of GS-9973 and how weel the drug is tolerated.

Clinical Study Identifier: TX3123

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Drashti Shah

AMITA Health
Arlington Heights, IL USA
  Connect »